179 related articles for article (PubMed ID: 14764640)
41. Hematologic effects of a novel hemoglobin-based oxygen carrier in normal male and female subjects.
Hughes GS; Francome SF; Antal EJ; Adams WJ; Locker PK; Yancey EP; Jacobs EE
J Lab Clin Med; 1995 Nov; 126(5):444-51. PubMed ID: 7595029
[TBL] [Abstract][Full Text] [Related]
42. Hemoglobin substitutes.
Anbari KK; Garino JP; Mackenzie CF
Eur Spine J; 2004 Oct; 13 Suppl 1(Suppl 1):S76-82. PubMed ID: 15168238
[TBL] [Abstract][Full Text] [Related]
43. Effects of hemoglobin glutamer-250 (bovine) (HBOC-201, Hemopure) on coagulation testing.
Jahr JS; Lurie F; Gosselin R; Lin JS; Wong L; Owings JT; Larkin E
Am J Ther; 2002; 9(5):431-6. PubMed ID: 12237736
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive Biochemical and Biophysical Characterization of Hemoglobin-Based Oxygen Carrier Therapeutics: All HBOCs Are Not Created Equally.
Meng F; Kassa T; Jana S; Wood F; Zhang X; Jia Y; D'Agnillo F; Alayash AI
Bioconjug Chem; 2018 May; 29(5):1560-1575. PubMed ID: 29570272
[TBL] [Abstract][Full Text] [Related]
45. Oxygen therapeutics--current concepts.
Hill SE
Can J Anaesth; 2001 Apr; 48(4 Suppl):S32-40. PubMed ID: 11336435
[TBL] [Abstract][Full Text] [Related]
46. Antioxidant effects of vitamin C on hemoglobin-based oxygen carriers derived from human cord blood.
Chen G; Duan Y; Liu J; Wang H; Yang C
Artif Cells Nanomed Biotechnol; 2016; 44(1):56-61. PubMed ID: 26671172
[TBL] [Abstract][Full Text] [Related]
47. Blood substitutes as pharmacotherapies in clinical practice.
Jahr JS; Walker V; Manoochehri K
Curr Opin Anaesthesiol; 2007 Aug; 20(4):325-30. PubMed ID: 17620840
[TBL] [Abstract][Full Text] [Related]
48. Confirmation and quantification of hemoglobin-based oxygen carriers in equine and human plasma by hyphenated liquid chromatography tandem mass spectrometry.
Guan F; Uboh CE; Soma LR; Luo Y; Jahr JS; Driessen B
Anal Chem; 2004 Sep; 76(17):5127-35. PubMed ID: 15373452
[TBL] [Abstract][Full Text] [Related]
49. Examples of doping control analysis by liquid chromatography-tandem mass spectrometry: ephedrines, beta-receptor blocking agents, diuretics, sympathomimetics, and cross-linked hemoglobins.
Thevis M; Schänzer W
J Chromatogr Sci; 2005 Jan; 43(1):22-31. PubMed ID: 15808003
[TBL] [Abstract][Full Text] [Related]
50. PEGylation promotes hemoglobin tetramer dissociation.
Caccia D; Ronda L; Frassi R; Perrella M; Del Favero E; Bruno S; Pioselli B; Abbruzzetti S; Viappiani C; Mozzarelli A
Bioconjug Chem; 2009 Jul; 20(7):1356-66. PubMed ID: 19534518
[TBL] [Abstract][Full Text] [Related]
51. Fetal oxygen content is restored after maternal hemorrhage and fluid replacement with polymerized bovine hemoglobin, but not with hetastarch, in pregnant sheep.
Moon PF; Bliss SP; Posner LP; Erb HN; Nathanielsz PW
Anesth Analg; 2001 Jul; 93(1):142-50. PubMed ID: 11429355
[TBL] [Abstract][Full Text] [Related]
52. Methods for detection and confirmation of Hematide™/peginesatide in anti-doping samples.
Leuenberger N; Saugy J; Mortensen RB; Schatz PJ; Giraud S; Saugy M
Forensic Sci Int; 2011 Dec; 213(1-3):15-9. PubMed ID: 21816551
[TBL] [Abstract][Full Text] [Related]
53. Applications and biomonitoring issues of recombinant erythropoietins for doping control.
Tsitsimpikou C; Kouretas D; Tsarouhas K; Fitch K; Spandidos DA; Tsatsakis A
Ther Drug Monit; 2011 Feb; 33(1):3-13. PubMed ID: 21099742
[TBL] [Abstract][Full Text] [Related]
54. Specific screening method for dextran and hydroxyethyl starch in human urine by size exclusion chromatography-in-source collision-induced dissociation-time-of-flight mass spectrometry.
Kolmonen M; Leinonen A; Kuuranne T; Pelander A; Deventer K; Ojanperä I
Anal Bioanal Chem; 2011 Aug; 401(2):563-71. PubMed ID: 21416163
[TBL] [Abstract][Full Text] [Related]
55. A review of blood substitutes: examining the history, clinical trial results, and ethics of hemoglobin-based oxygen carriers.
Chen JY; Scerbo M; Kramer G
Clinics (Sao Paulo); 2009; 64(8):803-13. PubMed ID: 19690667
[TBL] [Abstract][Full Text] [Related]
56. Resuscitation with a hemoglobin-based oxygen carrier after traumatic brain injury.
King DR; Cohn SM; Proctor KG
J Trauma; 2005 Sep; 59(3):553-60; discussion 560-2. PubMed ID: 16361895
[TBL] [Abstract][Full Text] [Related]
57. Does OxyVita, a new-generation hemoglobin-based oxygen carrier, or oxyglobin acutely interfere with coagulation compared with normal saline or 6% hetastarch? An ex vivo thromboelastography study.
Jahr JS; Weeks DL; Desai P; Lim JC; Butch AW; Gunther R; Driessen B
J Cardiothorac Vasc Anesth; 2008 Feb; 22(1):34-9. PubMed ID: 18249328
[TBL] [Abstract][Full Text] [Related]
58. Setbacks in blood substitutes research and development: a biochemical perspective.
Alayash AI
Clin Lab Med; 2010 Jun; 30(2):381-9. PubMed ID: 20513557
[TBL] [Abstract][Full Text] [Related]
59. Targeted O2 delivery by blood substitutes: in vitro arteriolar simulations of first- and second-generation products.
Cole R; Vandegriff K; Szeri A; Savas O; Winslow R
Microvasc Res; 2008 Nov; 76(3):169-79. PubMed ID: 18671987
[TBL] [Abstract][Full Text] [Related]
60. [Oxygen blood transport and doping].
Audran M; Connes P; Varlet-Marie E
Bull Acad Natl Med; 2003; 187(9):1669-79; discussion 1680-3. PubMed ID: 15369237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
